The facility now offers storage, kitting, and distribution of advanced therapies for clinical trials, specifically focusing on ultra-low temperature requirements
Catalent, a provider of improved treatments for patients worldwide, has announced the expansion of services and capabilities at its Shiga facility in Japan.
The facility now offers storage, kitting, and distribution of advanced therapies for clinical trials, specifically focusing on ultra-low temperature requirements.
The latest cryogenic freezers and material transfer equipment have been installed to ensure the preservation of investigational advanced therapy products, minimising their exposure to environmental conditions.
This expansion aligns with Catalent’s global strategy to strengthen its capacity in handling, storing, and managing advanced therapies for clinical supply. Similar investments have been made in specialised ultra-low temperature storage capabilities at facilities in Philadelphia, Singapore, and Shanghai, China.
The Shiga site, spanning 6,000m², opened in October 2021 to cater to local and global customers. It offers flexible clinical supply solutions, including primary packaging, Catalent’s FastChain demand-led supply, and meticulous handling and logistics services.
Catalent Japan president Tadahiro Matsumura said: “The market in Japan for advanced therapies and new modalities continues to grow, along with the demand for companies such as Catalent that have the advanced infrastructure to handle the supply and distribution of these highly sensitive products, as well as the specialised expertise and comprehensive knowledge to manage these supply chains.”
He added: “This investment allows us to provide the optimum logistical solution for every customer’s individual needs, and the foundation to increase capacity as requirements change and grow.”
With a presence in the US, the UK, Germany, Singapore, Japan, and China, complemented by an extensive network of over 50 depots, Catalent’s clinical supply services meet diverse international compliance and distribution requirements, ensuring comprehensive support for global clinical trials.